Astellas Pharma Inc. · Fiscal year ended March 2026

Five Astellas medicines added ¥143.9 billion in sales

Astellas develops and sells medicines for conditions including cancer and eye disease. Its major products, including XTANDI and PADCEV, are generally used by patients through prescriptions from healthcare professionals.

Building the next layer beside one enormous existing medicine

Five marketed medicines grew 43%

Different medicines serve different treatment needs

DATA VIEW

The five Strategic Brands have different sales scales

FY2025, year ended March 2026. Billions of yen, on one scale starting at 0. Individual product sales from the results presentation, p.6.

The five Strategic Brands have different sales scales
PADCEV¥221.2bn
IZERVAY¥77.6bn
VYLOY¥63.1bn
VEOZAH¥46.6bn
XOSPATA¥71.8bn

Source: FY2025 Financial Results, p.6

Providing medicines and investigating what comes next

Selling medicines and conducting research are different activities. Marketed medicines can also undergo development for additional indications.

Marketed major medicines

XTANDI, five Strategic Brands and others

Medicines for prescription
Healthcare professionals

Prescribe for the indicated use

Prescription
Patients

Use prescribed medicines in treatment

Research & development

Pharma, biotech and academia

External R&D partners

R&D partnerships
Astellas R&D teams

Combine internal researchers and external expertise

Investigate candidates and additional indications

Availability and approved indications vary by country or region. This is not a distribution or payment map, and does not guarantee approval, commercial availability or treatment outcomes for investigational uses.

Sources: Medicines and Disease Areas / Research and Development / Results presentation, p.8

Group revenue reached ¥2.1392 trillion

XTANDI is still the largest medicine

DATA VIEW

One product accounts for about 45% of group revenue

FY2025. XTANDI share is a site calculation.

One product accounts for about 45% of group revenue
XTANDI44.9%
All other revenue55.1%

The 55.1% remainder already includes the Strategic Brands

XTANDI and the five brands account for 67.4% of revenue

Research spans 15 internal sites and external partners

Research combines disease biology and treatment technologies

The business operates in more than 70 countries and regions

DATA VIEW

Current product sales and the cost of research

Sales and R&D expense are FY2025 figures. The 70-plus-country footprint comes from the company overview, not a same-year revenue breakdown.

¥960.8bnXTANDI
¥480.3bnFive Strategic Brands
¥314.8bnR&D expense
70+Countries and regions

Plans for marketed medicines and future candidates

THE VIEW AFTER THE NUMBERS

What the numbers suggest

Astellas sells medicines while researching future medicines and additional uses. The five Strategic Brands’ ¥143.9 billion increase is an achieved result; future pipeline sales potential is an expectation.

Alongside XTANDI’s ¥960.8 billion, the company is building sales of medicines for different conditions and conducting research internally and with partners. Understanding its progress means keeping current revenue, R&D expense and future ambitions separate.

Share this article

Share on X

Primary sources used

FY2025 Financial Results

Astellas Pharma Inc. · 2026-04-27

Pages used: p.2,5-6,8 / p.5 / p.5-6

Open source →

NEXT COMPANY

Tsubakimoto Chain Co. · Year ended March 2026

Look at the next company

Tsubakimoto meshes two chains to lift a load

Tsubakimoto uses chain geometry and motion to build equipment that pushes loads upward. ZIP CHAIN meshes two chains into a rigid column, then separates them for storage in a compact case. Its wider Chain and Motion Control businesses nevertheless had very different operating margins in the year ended March 2026: 15.1% and 4.1%. Their April 2026 combination aims to extend product combinations into customer proposals and after-sales service. Its earnings effects still need to be established through future results.

See the company through the numbers →
15.1%Chain operating margin, year ended March 2026